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Supplementary Figure S1.  Response of individual acyl chains to CGT inhibition 
in vivo.  LC-MS quantification of individual acyl chain forms of non-hydroxy-GalCer (A) 





Supplementary Figure S2.  Impact of S202 on testes.  Testes of wild-type mice 
treated with S202 from PND15 to PND70.    Compared to vehicle treated mice (A), the 
testes of S202 treated mice (B) showed seminiferous tubules with complete absence of 
spermatozoa and elongated spermatids, large numbers of intraluminal multinucleated 
giant cells, germ cell exfoliation with decreased germinal epithelial layers, and complete 






Supplementary Figure S3. Impact of S202 on glycosphingolipids in wild-type mice 
treated from PND15-70. 
Non-hydroxy-GalCer were reduced in brain (A) and sciatic nerve (B) in treated mice 
while 2-hydroxy-GalCer were less reduced in brain (C) and sciatic nerve (D).   Non-
hydroxy-ceramide levels were not significantly altered in brain and sciatic nerve from 
treated mice (E and F).  However, 2-hydroxy-ceramide levels in brain were greatly 




Supplementary Figure S4. Low dose treatment (0.15 mg/kg) starting on PND3-70 
produces similar brain vacuolation. 
Wild-type mice were treated from PND3 to PND70 with vehicle (A) or 0.15 mg/kg S202 
(B and C) and brains evaluated for the presence of vacuoles.   Vacuoles were found in 
the same regions as observed at higher doses when treatment was started on PND15.   
  
 
Enzymes tested S202 IC50 
CGT enzyme 15 nM 
CGT cellular 3 nM 
GCS >50 µM 
GBA1 >50 µM 
GBA2 >50 µM 
GALC >50 µM 
CST >50 µM 
ARSA >50 µM 
SMS >50 µM 
UGT1A >30 µM 
CB1R inverse agonist 2.1 µM 
CB1R antagonist 2.9 µM 
 
Supplementary Table S1. S202 CGT inhibition selectivity.  
S202 inhibitor activity against enzymes with related substrates.  Activity towards the 




  Vehicle S202 2.3 mg/kg S202 5.4 mg/kg 
  Avg SD Avg SD P value Avg SD P value 
ALT IU/L 84.8 70.5 257.2 169.5 0.008 99.5 67.2 0.96 
AST IU/L 155.7 74.2 283.5 106.8 0.010 132.8 47.9 0.83 
CKMB U/L 197.4 44.0 250.5 98.8 0.21 126.4 36.7 0.071 
NA mmol/L 146.4 3.4 148 2.0 0.53 150.9 2.6 0.015 
K mmol/L 9.9 1.1 10.5 1.3 0.45 9.6 0.6 0.84 
CL mmol/L 107.8 1.9 109.4 3.8 0.44 111.3 2.0 0.031 
WBC x10^3/µL 5.7 1.2 5.5 0.7 0.93 4.9 0.3 0.26 
RBC x10^6/µL 10.4 0.5 9.9 0.3 0.41 10.4 0.4 >0.99 
HGB g/dL 15.2 1.0 15.3 0.4 0.99 15.9 0.4 0.22 
HGBCell g/dL 13.4 0.5 13.2 0.2 0.78 13.7 0.4 0.53 
HCT % 50.1 2.1 47.9 0.9 0.34 50.1 1.7 >0.99 
MCV fL 48.2 0.9 48.2 0.5 >0.99 48.1 0.5 0.98 
MCH pg 14.6 0.8 15.4 0.1 0.28 15.3 0.2 0.13 
MCHC g/dL 30.3 1.8 31.9 0.1 0.32 31.8 0.5 0.14 
CH pg 12.9 0.3 13.3 0.2 0.19 13.1 0.2 0.45 
CHCM g/dL 26.7 0.2 27.5 0.1 0.03 27.3 0.4 0.024 
RDW % 12.7 0.4 12.2 0.4 0.11 11.8 0.3 0.0012 
HDW g/dL 1.91 0.05 1.9 0 0.71 1.93 0.03 0.69 
PLT x10^3/µL 817.3 258 1020.0 41 0.63 737.2 298 0.86 
PDW % 42.83 8.0 37.1 1.3 0.78 46.63 13.3 0.81 
MPV fL 5.5 0.21 5.4 0.1 0.82 5.82 0.39 0.21 
MPM pg 1.31 0.02 1.3 0.0 0.93 1.3 0.02 0.59 
%NEUT  16.9 6.8 14.3 1.9 0.84 11.4 5 0.26 
%LYMPH  72.5 8.4 78.8 3.4 0.62 77.6 8.5 0.55 
%MONO  3.0 1.1 2.3 0.6 0.53 1.6 0.6 0.040 
%EOS  5.8 2.6 2.4 1.0 0.65 8.2 6.2 0.64 
%BASO  0.4 0.14 0.4 0.0 >0.99 0.35 0.12 0.78 
%LUC  1.3 0.5 2 1.1 0.36 0.9 0.4 0.46 
%RETIC  3.2 0.4 2.9 0.8 0.63 2.7 0.3 0.13 
#RETIC 10^9cells/L 335 52.3 291 90.2 0.51 285 23.7 0.20 
CHR pg 15.1 0.6 14.6 0.1 0.24 14.6 0.1 0.10 
CHm pg 13.6 0.3 14 0.2 0.24 13.8 0.2 0.47 
#NEUT 10^3cells/µL 0.92 0.26 0.8 0.2 0.77 0.55 0.24 0.06 
#LYMPH 10^3cells/µL 4.2 1.2 4.3 0.3 0.99 3.8 0.5 0.69 
#MONO 10^3cells/µL 0.18 0.07 0.12 0.01 0.38 0.08 0.03 0.02 
#EOS 10^3cells/µL 0.32 0.11 0.14 0.08 0.59 0.4 0.31 0.81 
#BASO 10^3cells/µL 0.022 0.012 0.02 0.0 0.97 0.013 0.005 0.26 
#LUC 10^3cells/µL 0.073 0.031 0.11 0.07 0.40 0.047 0.021 0.38 
 
Supplementary Table S2. Clinical blood chemistry and blood cell counts for CGT 
inhibitor treated wild-type mice. 
Clinical chemistry and hematology from wild-type mice treated from PND15-PND70.  
For CBC n= 12 for vehicle and n= 6 for low and high dose groups.  For blood cell counts 
n=6 for vehicle and high dose group but n=2 for low dose group.  Statistics are 1-way 
ANOVA with Tukey post hoc analysis. 
 
 
